Development of a Class Prediction Model to Discriminate Pancreatic Ductal Adenocarcinoma from Pancreatic Neuroendocrine Tumor by MALDI Mass Spectrometry Imaging

Abstract

Purpose To define proteomic differences between pancreatic ductal adenocarcinoma (pDAC) and pancreatic neuroendocrine tumor (pNET) by matrix‐assisted laser desorption/ionization mass spectrometry imaging (MALDI MSI). Experimental design Ninety‐three pDAC and 126 pNET individual tissues are assembled in tissue microarrays and analyzed by MALDI MSI. The cohort is separated in a training (52 pDAC and 83 pNET) and validation set (41 pDAC and 43 pNET). Subsequently, a linear discriminant analysis (LDA) model based on 46 peptide ions is performed on the training set and evaluated on the validation cohort. Additionally, two liver metastases and a whole slide of pDAC are analyzed by the same LDA algorithm. Results Classification of pDAC and pNET by the LDA model is correct in 95% (39/41) and 100% (43/43) of patients in the validation cohort, respectively. The two liver metastases and the whole slide of pDAC are also correctly classified in agreement with the histopathological diagnosis. Conclusion and clinical relevance In the present study, a large dataset of pDAC and pNET by MALDI MSI is investigated, a class prediction model that allowed separation of both entities with high accuracy is developed, and differential peptide peaks with potential diagnostic, prognostic, and predictive values are highlighted.

Mass Spectrometry Imaging for Reliable and Fast Classification of Non-Small Cell Lung Cancer Subtypes

“…The classification of MSI data has been mainly performed using LDA and SVM [14][15][16][17][18][19][20]. An RF classification algorithm has previously been applied to classify MSI data but not on a large clinically relevant sample cohort [21,22].…”

Implementation of MALDI Mass Spectrometry Imaging in Cancer Proteomics Research: Applications and Challenges

“…Overexpression of this biomarker is associated with the diagnosis of malignant prostate cancer [ 35 ]. Extensive proteomic research with MALDI MSI was performed by Casadonte et al [ 36 ] on pancreatic ductal adenocarcinoma and pancreatic neuroendocrine tumor tissues, leading to the development of a class prediction model to differentiate between both entities with high accuracy, essential for the appropriate treatment modality. MALDI MSI proteomic analyses has also proven their relevance in triple-negative breast cancer in the search for putative markers for recurrence-free survival: Phillips et al [ 37 ] identified nine proteins, not previously associated with breast cancer, that were significantly associated with worse recurrence-free survival when these proteins were highly expressed.…”

Mass Spectrometry Imaging Differentiates Chromophobe Renal Cell Carcinoma and Renal Oncocytoma with High Accuracy

“…Among those, mass spectrometry imaging (MSI) has prompted interest among pathologists, as it combines the detection of multiple proteins or peptides with information about their topographical localization within tissue sections. The method was previously used to classify different cancer subtypes 12 - 14 . However, this technique has rarely been applied to study renal tumors and data on the differential expression patterns in cRCC and rO is lacking so far 15 - 17 .…”